Analyst consensus rating
BioNTech Analyst Rating: Buy
BNTX is rated Buy by 20 analysts with a $121.78 target. As of 2026-08-19.
Direct answer
BioNTech's consensus rating is Buy.
20 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $121.78.
Forecast evidence checked August 19, 2026.
Get free BioNTech email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $113.12
- Average price target
- $121.78
- High price target
- $145.97
- Low price target
- $77.08
- Low target gap
- -31.9%
- Target upside
- +7.7%
- High target gap
- +29%
- Target range width
- 60.9%
- Consensus rating
- Buy
- Analysts
- 20
- Evidence date
- August 19, 2026
- Valid through
- August 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BioNTech?
BioNTech has a verified Buy consensus. The same dataset has an average price target of $121.78.
How far are BioNTech's low and high targets from the recorded price?
The low target implies -31.9%, while the high target implies +29%.
How many analysts are included in BioNTech's consensus?
The verified consensus includes 20 analysts.
How is BioNTech's target upside or downside calculated?
The average target of $121.78 is divided by the recorded price of $113.12, then one is subtracted to produce +7.7%. This does not guarantee a future return.
When was BioNTech's analyst forecast verified?
The data was verified on 2026-08-19. The dataset is valid through 2026-08-26.